US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palvella Therapeutics

25.39

-0.0800-0.31%

Post-market: 25.390.00000.00%16:05 EDT

Volume:65.99K

Turnover:1.66M

Market Cap:279.77M

PE:-3.24

High:26.79

Open:25.06

Low:24.29

Close:25.47

Loading ...

Overview Company News Filings

Palvella Therapeutics Initiated at Buy by TD Cowen

Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.

BRIEF-Palvella Therapeutics Publishes Results From Phase 2 Clinical Trial Of Qtorin In The Journal Of Vascular Anomalies

Palvella Therapeutics Inc - Phase 3 Trial of Qtorin Rapamycin for Microcystic Lms With Data Expected Q1 2026

THOMSON REUTERS

Palvella Therapeutics Announces Publication of Results From Phase 2 Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

THOMSON REUTERS

Palvella Therapeutics Inc - Qtorin Rapamycin Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS

Palvella Therapeutics Inc - 100% Participants Show Improvement After 12 Weeks of Qtorin Rapamycin

THOMSON REUTERS

Palvella Doses 1st Patients in Phase 2 Study of Venous Malformation Treatment Drug

MT Newswires Live

BRIEF-Palvella Therapeutics Doses First Patients In Phase 2 Toiva Clinical Trial Of Qtorin

Palvella Therapeutics announces first patients dosed in Phase 2 TOIVA trial

Palvella Therapeutics Announces First Patients Dosed in Phase 2 Toiva Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Cutaneous Venous Malformations

THOMSON REUTERS

Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.

U.S. RESEARCH ROUNDUP-Apple, EverQuote, UnitedHealth

BUZZ-H.C. Wainwright starts coverage of Palvella Therapeutics with 'buy' rating

HC Wainwright Initiates Palvella Therapeutics With Buy Rating, $38 Price Target

MT Newswires Live

Palvella Therapeutics Initiated at Buy by HC Wainwright & Co.

Palvella Therapeutics initiated with a Buy at H.C. Wainwright

Optimistic Buy Rating for Palvella Therapeutics’ QTORIN Gel Due to Unmet Need and Market Potential

Palvella Therapeutics Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

Twelve option delistings on December 23rd

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PVLA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":25.39,"timestamp":1745611200000,"preClose":25.47,"halted":0,"volume":65991,"hourTrading":{"tag":"盘后","latestPrice":25.39,"preClose":25.39,"latestTime":"16:05 EDT","volume":119,"amount":3021.41,"timestamp":1745611513608},"delay":0,"floatShares":6292255,"shares":11018747,"eps":-7.832217,"marketStatus":"Market Closed","change":-0.08,"latestTime":"04-25 16:00:00 EDT","open":25.06,"high":26.79,"low":24.29,"amount":1656488.118,"amplitude":0.098155,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.832217,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":25.47,"preHourTrading":{"tag":"盘前","latestPrice":25.89,"preClose":25.47,"latestTime":"04:05 EDT","volume":2,"amount":49.239998,"timestamp":1745568323112},"postHourTrading":{"tag":"盘后","latestPrice":25.39,"preClose":25.39,"latestTime":"16:05 EDT","volume":119,"amount":3021.41,"timestamp":1745611513608},"volumeRatio":0.5812802236780464,"impliedVol":0.261,"impliedVolPercentile":0.3934},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":6292255,"roa":"-18.39%","roe":"-59.37%","lyrEps":-7.832217,"volumeRatio":0.5812802236780464,"shares":11018747,"dividePrice":0,"high":26.79,"amplitude":0.098155,"preClose":25.47,"low":24.29,"week52Low":6.2,"pbRate":"4.47","week52High":29.27,"institutionHeld":0,"latestPrice":25.39,"eps":-7.832217,"divideRate":0,"volume":65991,"delay":0,"ttmEps":-7.832217,"open":25.06,"prevYearClose":12,"prevWeekClose":24.36,"prevMonthClose":27.99,"prevQuarterClose":27.99,"fiveDayClose":24.36,"twentyDayClose":27.76,"sixtyDayClose":13.31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509640706","title":"Palvella Therapeutics Initiated at Buy by TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2509640706","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509640706?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:17","pubTimestamp":1738757820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 05, 2025 07:17 ET (12:17 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4566","PVLA","BK4127","BK4207","COWN","TD","BK4139"],"gpt_icon":0},{"id":"2502886303","title":"Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2502886303","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502886303?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:16","pubTimestamp":1736514960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 10, 2025 08:16 ET (13:16 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2502086369","title":"BRIEF-Palvella Therapeutics Publishes Results From Phase 2 Clinical Trial Of Qtorin In The Journal Of Vascular Anomalies","url":"https://stock-news.laohu8.com/highlight/detail?id=2502086369","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502086369?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:11","pubTimestamp":1736514707,"startTime":"0","endTime":"0","summary":"Jan 10  - Palvella Therapeutics Inc   :   * PALVELLA THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM PHASE 2 CLINICAL TRIAL OF QTORIN 3.9% RAPAMYCIN ANHYDROUS GEL  FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS IN THE JOURNAL OF VASCULAR ANOMALIES   * PALVELLA THERAPEUTICS INC - PHASE 3 TRIAL OF QTORIN RAPAMYCIN FOR MICROCYSTIC LMS WITH DATA EXPECTED Q1 2026   * PALVELLA THERAPEUTICS INC - QTORIN RAPAMYCIN WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS   * PALVELLA THERAPEUTICS INC - 100% PARTICIPANTS SHOW IMPROVEMENT AFTER 12 WEEKS OF QTORIN RAPAMYCINSource text:   Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2502868233","title":"Palvella Therapeutics Inc - Phase 3 Trial of Qtorin Rapamycin for Microcystic Lms With Data Expected Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2502868233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502868233?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA8JP7B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2502463868","title":"Palvella Therapeutics Announces Publication of Results From Phase 2 Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies","url":"https://stock-news.laohu8.com/highlight/detail?id=2502463868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502463868?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA8JP7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2502402868","title":"Palvella Therapeutics Inc - Qtorin Rapamycin Well-Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2502402868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502402868?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA8JP7B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2502086823","title":"Palvella Therapeutics Inc - 100% Participants Show Improvement After 12 Weeks of Qtorin Rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2502086823","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502086823?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA8JP7B:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2502777700","title":"Palvella Doses 1st Patients in Phase 2 Study of Venous Malformation Treatment Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2502777700","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502777700?lang=en_us&edition=fundamental","pubTime":"2025-01-09 00:42","pubTimestamp":1736354574,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) said Wednesday that first patients have been dosed in the phase 2 clinical trial of Qtorin 3.9% rapamycin anhydrous gel to treat cutaneous venous malformations.Venous malf","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2501720578","title":"BRIEF-Palvella Therapeutics Doses First Patients In Phase 2 Toiva Clinical Trial Of Qtorin","url":"https://stock-news.laohu8.com/highlight/detail?id=2501720578","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501720578?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:00","pubTimestamp":1736344837,"startTime":"0","endTime":"0","summary":"Jan 8 (Reuters) - Palvella Therapeutics Inc   :   * PALVELLA THERAPEUTICS ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2 TOIVA CLINICAL TRIAL OF QTORIN 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN RAPAMYCIN) FOR T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2501724266","title":"Palvella Therapeutics announces first patients dosed in Phase 2 TOIVA trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2501724266","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501724266?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:15","pubTimestamp":1736342141,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced the first patients have recently been dosed in TOIVA, a multicenter, Phase 2 clinical trial designed to eval...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2501972154","title":"Palvella Therapeutics Announces First Patients Dosed in Phase 2 Toiva Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Cutaneous Venous Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2501972154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501972154?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA68MDGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2500695192","title":"Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2500695192","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500695192?lang=en_us&edition=fundamental","pubTime":"2025-01-03 20:01","pubTimestamp":1735905660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 03, 2025 07:01 ET (12:01 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2494857422","title":"U.S. RESEARCH ROUNDUP-Apple, EverQuote, UnitedHealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2494857422","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494857422?lang=en_us&edition=fundamental","pubTime":"2024-12-26 21:03","pubTimestamp":1735218219,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apple, EverQuote, UnitedHealthDec 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apple, EverQu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241226:nL4N3NR0HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999018857.SGD","BK4185","BK4574","IE00BZ9MQY76.HKD","IE0003U64NQ7.SGD","LU0545039389.USD","LU0708994859.HKD","LU1206712785.SGD","LU1509826696.USD","LU2458330169.SGD","MACW.SI","PGR","UNH","HGTY","SGXZ31699556.SGD","LU1061106388.HKD","LU1003077747.HKD","LU1066051811.HKD","LU1267930490.SGD","LU0642271901.SGD","BK4550","IE00BZ1G4Q59.USD","ACVA","HK0000320223.HKD","LU0823434583.USD","LU1267930573.SGD","HK0000306701.USD","KMPR","RAPT","SG9999014542.SGD","LU1153585028.USD","LU1868837300.USD","BK4588","LU0788109477.HKD","SG9999001424.SGD","SG9999015341.SGD","LU0731783048.USD","AAPL","EVER","PVLA","LU0784385170.HKD","LU1506573853.SGD","AVXL","LU0417517546.SGD","LU0320765059.SGD","LU0345770308.USD","LU0957808578.USD","SGRY","SG9999011175.SGD","SG9999000418.SGD"],"gpt_icon":1},{"id":"2494285764","title":"BUZZ-H.C. Wainwright starts coverage of Palvella Therapeutics with 'buy' rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2494285764","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494285764?lang=en_us&edition=fundamental","pubTime":"2024-12-26 20:54","pubTimestamp":1735217674,"startTime":"0","endTime":"0","summary":"BUZZ-H.C. Wainwright starts coverage of Palvella Therapeutics with 'buy' rating** Brokerage H.C. Wainwright starts coverage of drug developer Palvella Therapeutics PVLA.O with \"buy\" rating and PT of $38 - a 3x upside to Tuesday's close** Co is testing a topical form of rapamycin called Qtorin in late-stage studies to treat two rare and chronic skin diseases called microcystic lymphatic malformations and cutaneous venous malformations** There is a high unmet need because no approved therapies exist for these conditions - H.C. Wainwright ** Brokerage says Palvella's formulation addresses critical limitations of other forms of the drug, such as poor skin penetration, systemic toxicity, and chemical instability** Says doctors have expressed optimism about the potential for a topical rapamycin therapy, as current treatments such as lasers, surgery or off-label medicines are either ineffective or only provide temporary relief ** Late-stage data from one of the trials is expected in early 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241226:nL4N3NR0GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2494685453","title":"HC Wainwright Initiates Palvella Therapeutics With Buy Rating, $38 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2494685453","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494685453?lang=en_us&edition=fundamental","pubTime":"2024-12-26 20:09","pubTimestamp":1735214987,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Palvella Therapeutics With Buy Rating, $38 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"gpt_icon":0},{"id":"2494593988","title":"Palvella Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2494593988","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494593988?lang=en_us&edition=fundamental","pubTime":"2024-12-26 19:25","pubTimestamp":1735212300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 26, 2024 06:25 ET (11:25 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2494560358","title":"Palvella Therapeutics initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2494560358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494560358?lang=en_us&edition=fundamental","pubTime":"2024-12-26 19:20","pubTimestamp":1735212005,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $38 price target Palvella’s lead product, QTORIN 3.9% rapa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2494856087","title":"Optimistic Buy Rating for Palvella Therapeutics’ QTORIN Gel Due to Unmet Need and Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2494856087","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494856087?lang=en_us&edition=fundamental","pubTime":"2024-12-26 19:15","pubTimestamp":1735211755,"startTime":"0","endTime":"0","summary":"Andrew Fein, an analyst from H.C. Wainwright, has initiated a new Buy rating on Palvella Therapeutics (PVLA). Andrew Fein’s rating is based on the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-palvella-therapeutics-qtorin-gel-due-to-unmet-need-and-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-palvella-therapeutics-qtorin-gel-due-to-unmet-need-and-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2494833856","title":"Palvella Therapeutics Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2494833856","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494833856?lang=en_us&edition=fundamental","pubTime":"2024-12-26 19:02","pubTimestamp":1735210966,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241226:nAZN2XORPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2493169750","title":"Twelve option delistings on December 23rd","url":"https://stock-news.laohu8.com/highlight/detail?id=2493169750","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493169750?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:35","pubTimestamp":1734960945,"startTime":"0","endTime":"0","summary":"Option delistings effective December 23rd include Pieris Pharmaceuticals (PVLA), Nanostring Technologies, Inc. (NSTGQ), NaaS Technology (NAAS), ROU...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/twelve-option-delistings-on-december-23rd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/twelve-option-delistings-on-december-23rd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAAS","BK4214","NSTGQ","BK4204","BK4121","PVLA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19},{"market":"US","date":"2024-08-14","symbol":"PVLA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-2.76},{"market":"US","date":"2024-05-15","symbol":"PVLA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-3.95},{"market":"US","date":"2024-04-23","symbol":"PVLA","defaultRemindTime":1713879000000,"type":"split","dateTimestamp":1713844800000,"forFactor":80,"toFactor":1,"ratio":80}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.8889,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8889,"analysts":9,"updateTime":1744257600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2025-04-25","current":-16.097711,"percent":0.037975,"low":-17.359106,"twenty":-12.583644,"median":23.043756,"eighty":39.236406,"high":46.119317,"avg":20.495462,"sd":20.299797,"marketCap":280647486},"quantilePoints":[{"date":"2025-01-03","current":19.083855,"twenty":19.083855,"median":19.083855,"eighty":19.083855,"marketCap":134655684},{"date":"2025-01-10","current":22.662078,"twenty":19.083855,"median":20.077806,"eighty":23.120091,"marketCap":159903624},{"date":"2025-01-17","current":21.024047,"twenty":19.083855,"median":21.024047,"eighty":22.483962,"marketCap":148345678},{"date":"2025-01-24","current":20.658273,"twenty":19.395558,"median":20.960435,"eighty":22.003685,"marketCap":145764777},{"date":"2025-01-31","current":21.469337,"twenty":19.914003,"median":20.93658,"eighty":21.408905,"marketCap":151487644},{"date":"2025-02-07","current":23.854819,"twenty":20.19708,"median":20.960435,"eighty":22.191343,"marketCap":168319605},{"date":"2025-02-14","current":31.806426,"twenty":20.537409,"median":21.047902,"eighty":23.471552,"marketCap":224426140},{"date":"2025-02-21","current":30.216104,"twenty":20.626467,"median":21.159225,"eighty":24.999851,"marketCap":213204833},{"date":"2025-02-28","current":29.977556,"twenty":20.64237,"median":22.089563,"eighty":29.977556,"marketCap":211521636},{"date":"2025-03-07","current":38.072292,"twenty":20.658273,"median":23.043756,"eighty":30.804523,"marketCap":268638089},{"date":"2025-03-14","current":43.224933,"twenty":20.674177,"median":23.473142,"eighty":31.806426,"marketCap":304995124},{"date":"2025-03-21","current":43.622513,"twenty":20.674177,"median":24.864674,"eighty":35.527777,"marketCap":307800451},{"date":"2025-03-28","current":44.147319,"twenty":20.912725,"median":26.844623,"eighty":43.224933,"marketCap":311503482},{"date":"2025-04-04","current":-15.431096,"twenty":20.674177,"median":26.264156,"eighty":43.368061,"marketCap":269025725},{"date":"2025-04-11","current":-12.558363,"twenty":20.515145,"median":24.729496,"eighty":43.224933,"marketCap":218942502},{"date":"2025-04-17","current":-15.421442,"twenty":19.083855,"median":23.473142,"eighty":40.654974,"marketCap":268857426},{"date":"2025-04-25","current":-16.097711,"twenty":-12.583644,"median":23.043756,"eighty":39.236406,"marketCap":280647486}],"updateTime":1745784845193}}}